repurpose-mcp
Provides literature search through PubMed/NCBI E-utilities, retrieving articles that mention both a drug and a disease, with PMID, title, year, and journal.
This server does not currently have a deployable release on Glama. Follow the repository's setup instructions to install and configure it for your MCP client, including any required credentials and local dependencies.
repurpose-mcp
An MCP server that helps rare disease clinicians and trial teams find approved drugs, probably off-patent, with a plausible mechanism for a disease. Every claim it makes is traceable to a public record: an Open Targets or ChEMBL ID, a ClinicalTrials.gov NCT number, or a PubMed PMID.
It is a hypothesis-generation tool for research teams, not a source of clinical advice.
Key finding
The pipeline mostly re-finds repurposing that has already been trialled. It almost never predicts it.
Recall@10 on 7 known repurposing cases | Result |
Standard Open Targets association scores | 4/7 |
With prior clinical evidence ( | 0/7 |
Standard scores include each drug's own trials for the disease, so the first number is partly circular. The second is closer to real prospective use, and it drops to zero.
The main reason is mechanistic. The tool only finds drugs that act directly on a disease-linked gene. Classic repurposing often works downstream. In LAM the disease gene is TSC2, but sirolimus acts on mTOR (via FKBP1A), a different protein further along the same pathway. Closing that gap, for example with one-hop pathway expansion, is the next step.
Cases are in evals/known_cases.csv, each checked against a primary
source (trial registration, publication or regulatory approval). They cover five approved
repurposings, one positive trial and one negative trial. Full results:
evals/results.md.
Related MCP server: KnowS MCP Server
What it does
Ask Claude (Desktop or Code) for a repurposing brief on a disease. Claude then uses five tools that query public databases live:
Step | Tool | Source | What you get |
1 |
| Open Targets Platform | Disease ID (MONDO/EFO/Orphanet) and name, with alternatives |
2 |
| Open Targets Platform | Genes/proteins most associated with the disease, with an overall score and a score per evidence type (genetics, somatic mutations, literature, animal models, prior clinical use…) |
3 |
| Open Targets + ChEMBL | Approved drugs acting on those targets: ChEMBL ID, mechanism of action, first approval year, approved indications, withdrawn flag, and a |
4 |
| ClinicalTrials.gov API v2 | Trials of the drug in the disease: NCT ID, title, phase, status, enrolment |
5 |
| PubMed (NCBI E-utilities) | Articles mentioning both drug and disease: PMID, title, year, journal |
The repurposing_brief prompt chains these together and asks Claude to produce one evidence table:
Drug | Target | Mechanism | Approval year | Off-patent heuristic | Trials | PMIDs | Evidence strength | Gaps |
The prompt forbids uncited claims ("no claim without an ID") and invented identifiers. It also requires a grade for evidence strength (Strong / Moderate / Weak / Mechanistic only) based only on the records retrieved, and a stated reason for any downgrade.
Example output
Excerpt from a brief for lymphangioleiomyomatosis (LAM), produced 2026-11-17 with Open Targets data
release 26.09 (full brief: evals/briefs/lymphangioleiomyomatosis.md):
Disease: lymphangioleiomyomatosis (MONDO_0011705) · Open Targets data 26.09
Drug
Target
Mechanism
Approval year
Off-patent heuristic
Trials
PMIDs
Evidence strength
Gaps
NINTEDANIB (CHEMBL502835)
PDGFRB (ENSG00000113721, 0.10); FGFR4, FLT4, FGFR2
PDGFR / VEGFR / FGFR inhibitor
2014 (ChEMBL)
unlikely (heuristic)
NCT03062943 (Ph2, completed, n=30)
PMID:39489895
Moderate
Downgraded from Strong: single-arm, open-label. No randomised comparison with sirolimus.
CELECOXIB (CHEMBL118)
PTGS2 (ENSG00000073756, 0.09)
Cyclooxygenase-2 inhibitor
1998 (ChEMBL)
likely (heuristic)
NCT02484664 (Ph2, completed, n=12)
PMID:32060062
Weak
12-participant pilot; the publication reports a phase I trial. Weak target association.
IMATINIB (CHEMBL941)
PDGFRB (0.10); ABL1 (0.09)
ABL / PDGFR-beta inhibitor
2001 (ChEMBL)
likely (heuristic)
NCT03131999 (Ph1/2, completed, n=18); NCT06889168 (Ph1, recruiting)
none found
Weak
Pilot with n<20; no published LAM results retrieved.
Already approved for this disease: SIROLIMUS (CHEMBL413). NCT00414648 (Ph3, n=89); PMID:31429781.
Limitations: read before using results
Not clinical advice. Output is a starting point for expert review, ethics and regulatory processes, not a treatment recommendation.
likely_off_patentis a heuristic. It is true when the first approval year is at least 20 years ago. It does not search patents. Formulation, method-of-use, paediatric and orphan exclusivities can outlast the compound patent. Old biologics may have no biosimilar. Generic availability differs by country. Verify in the FDA Orange Book (small molecules), Purple Book (biologics), or your national equivalent.Approval year source. First approval year comes from ChEMBL
first_approval(largely US FDA). When ChEMBL has no year, it falls back to the earliest regulatory approval in Open Targets (often EMA), which can understate a drug's age. Theapproval_year_sourcefield says which was used.Association scores are not efficacy evidence. An Open Targets score (0–1) summarises how much evidence links a gene to a disease. It says nothing about whether a drug acting on that gene helps patients. The "clinical" evidence type means drugs have already been trialled, so targets of already-tested drugs score higher.
Direct targets only. Drugs are found only if they act directly on an associated target. Drugs that act downstream of a disease gene are missed unless that target is itself associated. For example, sirolimus acts downstream of TSC2 loss in LAM. The recall eval shows how large this blind spot is (see below).
Searches are imperfect. ClinicalTrials.gov and PubMed expand synonyms, so results can include irrelevant records. For example, a "temsirolimus" trial search returns sirolimus trials. They can also miss relevant ones (non-English, unindexed, conference abstracts, unregistered trials). Read the titles.
Mechanism annotations are coarse. For example, tacrolimus and sirolimus share the ChEMBL "FKBP1A inhibitor" annotation but act on different downstream pathways.
Data freshness. Results reflect the live databases on the day you run them. Open Targets releases quarterly.
Install
You need uv and an internet
connection. Then download or clone this folder, for example to C:\tools\repurpose_mcp or
~/tools/repurpose_mcp, and run uv sync inside it once.
An NCBI API key is optional but recommended: it raises PubMed's rate limit from 3 to 10 requests
per second. You can get one free from your NCBI account settings. Set it as NCBI_API_KEY.
Claude Desktop
Open Settings → Developer → Edit Config and add the server to claude_desktop_config.json:
{
"mcpServers": {
"repurpose-mcp": {
"command": "uv",
"args": ["run", "--directory", "/ABSOLUTE/PATH/TO/repurpose_mcp", "python", "-m", "repurpose_mcp"],
"env": { "NCBI_API_KEY": "optional-your-key" }
}
}
}On Windows use a path like "C:\\tools\\repurpose_mcp". If Claude Desktop cannot find uv, put
the full path to the uv executable in command (where uv on Windows, which uv on macOS).
Restart Claude Desktop. To run the brief, click + → repurpose-mcp → repurposing_brief,
enter the disease, and send.
Claude Code
claude mcp add repurpose-mcp -e NCBI_API_KEY=your-key -- uv run --directory /ABSOLUTE/PATH/TO/repurpose_mcp python -m repurpose_mcpThen type /mcp__repurpose-mcp__repurposing_brief "Erdheim-Chester disease", or just ask, for
example "find approved drugs that might be repurposed for Castleman disease, with sources".
The configs use
python -m repurpose_mcprather than therepurpose-mcpconsole script. Windows Smart App Control can block the unsigned launcher.exethat uv generates.
Evaluations
uv run python evals/run.py writes evals/results.md. It has two parts:
(a) Citation integrity. For each brief in evals/briefs/, every PMID and NCT ID is fetched
and checked. A citation passes if the record exists and mentions both the drug of its table row
(name, trade names or curated synonyms) and the disease (name or synonyms). To check your own
brief, save Claude's output as a .md file in that folder, or run with --brief file.md. Passing
means the record is real and on topic; it does not mean the record supports the claim made.
(b) Recall on known repurposing cases. For each case in evals/known_cases.csv, the eval
checks whether the expected drug is in the top N candidates (default 10). Candidates are ranked by
their best target association score. CSV columns:
disease,expected_drug,disease_id,expected_chembl_id,notes
lymphangioleiomyomatosis,sirolimus,MONDO_0011705,CHEMBL413,approved for LAM 2015Only disease and expected_drug are required. Give disease_id to avoid mis-resolving the
disease name, and expected_chembl_id for exact drug matching. Until you add your verified file,
the eval uses evals/known_cases.example.csv (unverified examples) and says so in the results.
Recall runs twice. default uses standard Open Targets scores, which include the known repurposing's own trials, so the test is partly circular. no_clinical zero-weights that clinical evidence, which is closer to finding something new. On the example cases (2026-11-17), recall@10 was 4/7 by default and 0/7 with clinical evidence removed. In practice, the tool re-surfaces repurposing that is already in the clinical record much more reliably than it predicts new repurposing, mainly because of the direct-target limitation above.
Development
uv sync
uv run pytest # offline: replays recorded API responses (tests/cassettes)
REPURPOSE_RECORD=1 uv run pytest # re-record against the live APIsEngineering notes:
Requests use httpx with timeouts and up to four attempts, with exponential backoff and
Retry-Aftersupport, on 429/5xx and network errors.Rate limiting is per host: Open Targets and ChEMBL 5/s, ClinicalTrials.gov ~50/min, NCBI 3/s (10/s with a key).
A 6-hour in-memory cache serves repeat queries.
Tools return typed pydantic models, exposed as MCP structured output.
Schemas were checked against Open Targets API 26.9 and mcp 2.3.0 (where FastMCP is named
MCPServer). Open Targets removedknownDrugsandyearOfFirstApproval: this server usesdrugAndClinicalCandidatesand theAPPROVALclinical stage, and takes approval years from ChEMBL.
Tool Schema Changelog
Recent tool additions, removals, and schema changes observed during successful MCP inspections.
Loading tool schema changelog…
This server cannot be deployed
Maintenance
Related MCP Connectors
Coverage-honest drug-target intelligence: coverage grid, claim checks and audits, dossiers (5 tools)
Semantic search across 5 US government healthcare databases.
Free medical evidence tools: graded CliniAtlas answers, PubMed metadata and EU SmPC links.
Drug pipelines from public trial registries and regulators: every drug for a disease, with sources.
Related MCP Servers
- AlicenseBqualityDmaintenanceEnables comprehensive medical research by querying and analyzing data across ClinicalTrials.gov, PubMed, and FDA databases with AI-enhanced cross-database insights, risk assessments, and competitive intelligence.1311MIT
- AlicenseBqualityBmaintenanceEnables medical evidence retrieval and analysis via AI-powered search and summarization tools.149 npm1MIT
- AlicenseAqualityDmaintenanceEnables biopharma catalyst research by aggregating signals from ClinicalTrials.gov, PubMed, SEC EDGAR, openFDA, and Yahoo Finance, with a single tool to audit a ticker/drug combination and return a forensic verdict.181038 npm5ISC
- FlicenseAqualityDmaintenanceEnables interaction with synthetic NIH-style clinical research data through tools for searching publications, querying patient metadata, analyzing AAA measurements, and retrieving protocol guidance.5-